Scientific breakthroughs in blood cancer are advancing faster than ever. For community-based oncologists, staying current with the latest research and treatment innovations, especially those coming from top academic centers, can be a real challenge.

That’s why we created Treating Blood Cancer in the Community, a cost-free, independent video resource designed to deliver concise, expert insights directly to you and your clinical team.

Through short, high-impact clips, leading clinician-researchers from institutions such as Memorial Sloan Kettering, Mount Sinai, and others share how they are evolving care based on the most recent clinical trial data and drug approvals. Just as importantly, they offer guidance on how academic and community oncology teams can work together to improve patient outcomes.

Now Available: Diffuse Large B-Cell Lymphoma

​In this video, lymphoma expert Dr. Joshua Brody shares key insights on:

• The emerging role of bispecific antibodies in first- and second-line DLBCL treatment
• How he collaborates with community oncologists to manage treatment-related side effects

“Bispecific antibodies are absolutely transformational. We are already using them every day in third line and sometimes in second line DLBCL, by themselves and in combination with chemotherapies. These will unquestionably become part of second line therapy, and in my opinion, for DLBCL, in the very near future as part of frontline therapy.”  - Joshua Brody, MD, Director, Lymphoma Immunotherapy Program, Tisch Cancer Institute at Mount Sinai

Coming Soon: New Video Insights on

• Multiple Myeloma
  • Transplant eligible vs ineligible treatment 
  • Steroid dosing options
  • Infection prevention: IVIG, immunizations and diet
• Chronic Lymphocytic Leukemia
  • Supporting CLL patients in active surveillance
  • Helping patients choose: fixed-duration or continuous therapy
  • Treatment sequencing and switching drug class
• Acute Myeloid Leukemia
  • Elderly patients with AML
  • Key infection prophylaxis strategies in AML
  • Essential supportive measures during AML therapy
  • Transplant decisions in AML patients
  • New targeted therapy for KMT2A-rearranged relapsed/refractory AML
• Acute Lymphocytic Leukemia
  • How and when: collaboration with a specialized center
  • Successfully delivering blinatumomab to ALL patients
  • Addressing common toxicities in ALL treatment
• Myelofibrosis
  • Why early specialist referral matters in myelofibrosis
  • When to talk to a patient about a potential transplant
  • Monitoring and managing infection risk and toxicities
• Myelodysplastic Syndromes
  • The role of molecular testing in MDS management
  • ESA strategies and when to use luspatercept
  • Practical infection prevention in neutropenic MDS care
  • What’s new in MDS care?

Recent studies show that treatment approaches can vary between academic and community settings. These brief, expert-led segments are designed to support your practice by offering timely insights from academic leaders, delivered in a format that fits your busy schedule.

Support Your Patients With Free Educational Materials

Order patient-friendly booklets and resources to help your patients better understand their blood cancer diagnosis and treatment options.

The Story Behind HealthTree Foundation

Founded by myeloma patient and advocate Jenny Ahlstrom, HealthTree exists to close gaps in education, support, and research for blood cancer patients. What began as one patient's journey has grown into a comprehensive platform that empowers patients with knowledge and connection, while accelerating scientific discovery. Learn more about our story and mission.